þ cells collected from bone marrows and spleens of NSG mice formed colonies in vitro, and vitamin E treatment did not affect the engraftment (Figure 1b) . Imatinib-resistant clones carrying either E255K or T315I BCR-ABL1 kinase mutations were detected in three out of five untreated xenografts, but in none of the vitamin E-treated samples (Table 1 ).
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase Leukemia (2013) 27, 2254-2256; doi:10.1038/leu.2013.129
Several cooperative study groups and single institutions have reported on high rates of rapid and durable complete hematologic (CHR) and complete molecular remissions (CMR) on imatinib in eosinophilia-associated myeloid/lymphoid neoplasms (MLN-Eo) with rearrangements of PDGFR (PDGFRA and PDGFRB) in chronic phase (CP). These responses have translated into vastly improved progression-free and overall survival (OS). [1] [2] [3] [4] [5] [6] [7] [8] [9] In this report, we present data from the 'German Registry on Disorders of Eosinophils and Mast Cells' on long-term follow-up of 17 patients primarily diagnosed in blast phase (BP). BP was defined as (i) myeloid BP (420% blasts in peripheral blood (PB) and/or bone marrow (BM)), (ii) chloroma (extramedullary tissue infiltration by myeloid blasts) or (iii) extramedullary lymphoid BP (lymph node (LN) infiltration by lymphoblasts of T-cell origin).
Thirteen patients were FIP1L1-PDGFRA-positive (myeloid BP, n ¼ 8; chloroma, n ¼ 2; lymphoid BP, n ¼ 3). In all three patients investigated, FIP1L1-PDGFRA could be identified contemporaneously in myeloid cells derived from BM and CD3-positive lymphoblasts in LN biopsies. Four patients (myeloid BP, n ¼ 2; lymphoid BP, n ¼ 2) were positive for a rearrangement of PDGFRB (partner genes: ETV6, n ¼ 1; SART3, n ¼ 1; unknown partner gene, n ¼ 2). 10 All patients were male, median age was 46 years (range 37-66). Significant eosinophilia 41.5 Â 10 9 /l (median 7.7 Â 10 9 /l, range 1.3-20.7) was present in 12 of 13 (92%) FIP1L1-PDGFRApositive patients and 2 of 4 (50%) patients (median 1.2 Â 10 9 /l, range 0.1-33.0) with rearrangements of PDGFRB. In addition to the specific morphologic features of PB, BM and LN, the most common clinical characteristics included splenomegaly (17/17, 100%), involvement of lung (4/17, 24%; pleural effusion, n ¼ 4), skin (4/17, 24%) and heart (2/17, 12%; endo-/myocarditis, n ¼ 1; intracardial thrombus, n ¼ 1).
Without initial knowledge of the underlying fusion gene, nine patients received primary chemotherapy according to protocols Accepted article preview online 25 April 2013; advance online publication, 21 May 2013 for acute leukemia or lymphoma. 11 Despite clear signs of remission, for example, clearance of blasts or partial/complete clinical and/or hematologic remission, eosinophilia persisted at various levels in all nine patients. The underlying involvement of PDGFRA (FIP1L1-PDGFRA, n ¼ 6) or PDGFRB (n ¼ 3) was therefore only identified weeks or even months after initial morphological diagnosis by PCR, cytogenetics and/or fluorescence in situ hybridization and imatinib was initiated in 7 of 9 (78%) patients. In 8 of 17 patients (47%), the PDGFR rearrangement (FIP1L1-PDGFRA, n ¼ 7; PDGFRB, n ¼ 1) was already identified at diagnosis and imatinib was initiated directly. Overall, CHR was achieved in all 15 imatinib-treated patients (starting dose 400 mg/day, n ¼ 6; 100 mg/day, n ¼ 9) after median 1 month (0.1-14). CMR was detected in all 12 FIP1L1-PDGFRA-positive patients after median 5 months (3-32). One patient died due to a cerebral hemorrhage while in CMR for 9 months. The remaining 11 patients are in sustained CMR for median 65 months . The three patients with a PDGFRB rearrangement are in sustained CHR for median 56 months (24-56). Two patients (FIP1L1-PDGFRA, n ¼ 1; ETV6-PDGFRB plus complex karyotype, n ¼ 1) received an allogeneic stem cell transplantation (SCT) within 6 months (related donor, n ¼ 1; unrelated donor, n ¼ 1) after diagnosis of myeloid BP and lack of complete remission after intensive chemotherapy. Both patients relapsed early (o3 months). Following relapse, the FIP1L1-PDGFRA-positive patient was treated with imatinib (100 mg/day) and is in sustained CMR þ 9 months after SCT. The ETV6-PDGFRB-positive patient died due to progressive leptomeningeal involvement 9 months after SCT and 12 months after diagnosis of myeloid BP despite achievement of CHR in PB and BM on imatinib, which was initiated þ 1 month after SCT. Overall, only 2 of 17 (12%) patients have died after a median observation time of 65 months (range 7-106), which is not different as compared to 46 patients in CP (median 51 months, range 1-103; Figure 1a and b) .
Besides the excellent and sustained responses to imatinib in PDGFR fusion gene-positive MLN-eo in BP, our data also underscore the failure of standard diagnostic work-up at initial diagnosis to identify pathogenetically relevant tyrosine kinase (TK) fusion genes, for example, PDGFRA, PDGFRB or FGFR1, in patients with eosinophilia and supposed 'acute myeloid leukemia (AML)' or 'T-cell lymphoma'. It is noteworthy that the frequency of so called 'T-cell lymphomas' is even more frequent in patients with FGFR1 fusion genes as consequence of reciprocal translocations with involvement of 8p11, particularly in t(8;13)(p11;q13) with a ZNF198-FGFR1 fusion gene. 12 Careful attention should therefore be paid to the potential presence of these TK fusion genes in primarily diagnosed myeloid and lymphoid malignancies through distinctive clinical (for example, splenomegaly), biochemical (for example, elevated serum levels of tryptase or vitamin B12), morphological (for example, leukocytosis with left-shift and dysplasia, eosinophilia, fibrosis and/or increased numbers of loosely scattered mast cells in BM) and molecular genetic (for example, FIP1L1-PDGFRA, reciprocal translocations with involvement of 4q12-PDGFRA, 5q33-PDGFRB or 8p11-FGFR1) features of an eosinophilia-associated and TK fusion-positive stem cell disorder with involvement of the myeloid and lymphoid lineage. Having established the presence of a fusion gene, we consider that the diagnosis of these cases should be revised to 'myeloid BP' and 'extramedullary lymphoid BP' of MLNeo, respectively, the latter reflecting the fact that these are stem cell disorders in which affected TK fusion gene-positive T-lymphoblasts predominantly reside in the LN.
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In conclusion, our data highlight several new aspects for diagnosis and treatment of MLN-eo with PDGFR fusion genes: (i) mimicking de novo AML and T-cell lymphoma, myeloid and lymphoid BP of MLN-eo with an underlying imatinib-sensitive PDGFR fusion gene is frequently not identified, (ii) in the absence of CBF fusion genes, patients with eosinophilia-associated AML but also patients with eosinophilia-associated T-cell lymphoma should be actively screened for PDGFR fusion genes by PCR, cytogenetics and/or fluorescence in situ hybridization and (iii) the excellent long-term data for patients with MLN-eo in BP suggest that monotherapy with imatinib should be initiated early because durable remissions may only rarely be achieved through intensive chemotherapy or allogeneic SCT. 
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